Biologic therapies for psoriasis

Lauren Marie Guggina, Kenneth B. Gordon*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is possible to suggest that the past two decades have led to greater advances in the treatment of extensive psoriasis than almost any other disease. The number of treatments available has grown tremendously and our treatment goals have changed radically. While at the turn of the century it was thought that complete clearance of psoriasis in patients who had extensive disease was not feasible in almost any patient, we now have medications that can attain complete clearance in up to 40 % of patients. With achievement of higher levels of response, a new understanding of the benefit of these responses to patients has identified a need for greater responses. The development of targeted biologic immunotherapy for psoriasis has historically relied on the understanding of the pathophysiology of disease. However, the targeted nature0 of these medications, in concert with fortuitous clinical observation, has furthered the understanding of the pathological mechanisms in psoriasis. In turn, new insight has led to even more effective treatments. Thus, the use and study of biologics improves disease treatment in two ways. Their targeted nature can promote individual health by helping to treat the patient's disease while their study leads to global benefit by directing the creation of newer treatments. In this chapter, we will examine how biologics have changed our understanding of psoriasis and has led to the development of a multitude of new and exciting treatments.

Original languageEnglish (US)
Title of host publicationClinical and Basic Immunodermatology
Subtitle of host publicationSecond Edition
PublisherSpringer International Publishing
Pages757-765
Number of pages9
ISBN (Electronic)9783319297859
ISBN (Print)9783319297835
DOIs
StatePublished - Apr 24 2017

Fingerprint

Biological Therapy
Psoriasis
Biological Products
Therapeutics
Immunotherapy
Observation
Health

Keywords

  • Biologic therapy
  • Cytokines
  • IL17
  • IL23
  • Immunotherapy
  • Psoriasis
  • T cells
  • Th17

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Guggina, L. M., & Gordon, K. B. (2017). Biologic therapies for psoriasis. In Clinical and Basic Immunodermatology: Second Edition (pp. 757-765). Springer International Publishing. https://doi.org/10.1007/978-3-319-29785-9_43
Guggina, Lauren Marie ; Gordon, Kenneth B. / Biologic therapies for psoriasis. Clinical and Basic Immunodermatology: Second Edition. Springer International Publishing, 2017. pp. 757-765
@inbook{2d7288400cd7461a8f0c0f2411c48fdb,
title = "Biologic therapies for psoriasis",
abstract = "It is possible to suggest that the past two decades have led to greater advances in the treatment of extensive psoriasis than almost any other disease. The number of treatments available has grown tremendously and our treatment goals have changed radically. While at the turn of the century it was thought that complete clearance of psoriasis in patients who had extensive disease was not feasible in almost any patient, we now have medications that can attain complete clearance in up to 40 {\%} of patients. With achievement of higher levels of response, a new understanding of the benefit of these responses to patients has identified a need for greater responses. The development of targeted biologic immunotherapy for psoriasis has historically relied on the understanding of the pathophysiology of disease. However, the targeted nature0 of these medications, in concert with fortuitous clinical observation, has furthered the understanding of the pathological mechanisms in psoriasis. In turn, new insight has led to even more effective treatments. Thus, the use and study of biologics improves disease treatment in two ways. Their targeted nature can promote individual health by helping to treat the patient's disease while their study leads to global benefit by directing the creation of newer treatments. In this chapter, we will examine how biologics have changed our understanding of psoriasis and has led to the development of a multitude of new and exciting treatments.",
keywords = "Biologic therapy, Cytokines, IL17, IL23, Immunotherapy, Psoriasis, T cells, Th17",
author = "Guggina, {Lauren Marie} and Gordon, {Kenneth B.}",
year = "2017",
month = "4",
day = "24",
doi = "10.1007/978-3-319-29785-9_43",
language = "English (US)",
isbn = "9783319297835",
pages = "757--765",
booktitle = "Clinical and Basic Immunodermatology",
publisher = "Springer International Publishing",

}

Guggina, LM & Gordon, KB 2017, Biologic therapies for psoriasis. in Clinical and Basic Immunodermatology: Second Edition. Springer International Publishing, pp. 757-765. https://doi.org/10.1007/978-3-319-29785-9_43

Biologic therapies for psoriasis. / Guggina, Lauren Marie; Gordon, Kenneth B.

Clinical and Basic Immunodermatology: Second Edition. Springer International Publishing, 2017. p. 757-765.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Biologic therapies for psoriasis

AU - Guggina, Lauren Marie

AU - Gordon, Kenneth B.

PY - 2017/4/24

Y1 - 2017/4/24

N2 - It is possible to suggest that the past two decades have led to greater advances in the treatment of extensive psoriasis than almost any other disease. The number of treatments available has grown tremendously and our treatment goals have changed radically. While at the turn of the century it was thought that complete clearance of psoriasis in patients who had extensive disease was not feasible in almost any patient, we now have medications that can attain complete clearance in up to 40 % of patients. With achievement of higher levels of response, a new understanding of the benefit of these responses to patients has identified a need for greater responses. The development of targeted biologic immunotherapy for psoriasis has historically relied on the understanding of the pathophysiology of disease. However, the targeted nature0 of these medications, in concert with fortuitous clinical observation, has furthered the understanding of the pathological mechanisms in psoriasis. In turn, new insight has led to even more effective treatments. Thus, the use and study of biologics improves disease treatment in two ways. Their targeted nature can promote individual health by helping to treat the patient's disease while their study leads to global benefit by directing the creation of newer treatments. In this chapter, we will examine how biologics have changed our understanding of psoriasis and has led to the development of a multitude of new and exciting treatments.

AB - It is possible to suggest that the past two decades have led to greater advances in the treatment of extensive psoriasis than almost any other disease. The number of treatments available has grown tremendously and our treatment goals have changed radically. While at the turn of the century it was thought that complete clearance of psoriasis in patients who had extensive disease was not feasible in almost any patient, we now have medications that can attain complete clearance in up to 40 % of patients. With achievement of higher levels of response, a new understanding of the benefit of these responses to patients has identified a need for greater responses. The development of targeted biologic immunotherapy for psoriasis has historically relied on the understanding of the pathophysiology of disease. However, the targeted nature0 of these medications, in concert with fortuitous clinical observation, has furthered the understanding of the pathological mechanisms in psoriasis. In turn, new insight has led to even more effective treatments. Thus, the use and study of biologics improves disease treatment in two ways. Their targeted nature can promote individual health by helping to treat the patient's disease while their study leads to global benefit by directing the creation of newer treatments. In this chapter, we will examine how biologics have changed our understanding of psoriasis and has led to the development of a multitude of new and exciting treatments.

KW - Biologic therapy

KW - Cytokines

KW - IL17

KW - IL23

KW - Immunotherapy

KW - Psoriasis

KW - T cells

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=85035351769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035351769&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-29785-9_43

DO - 10.1007/978-3-319-29785-9_43

M3 - Chapter

AN - SCOPUS:85035351769

SN - 9783319297835

SP - 757

EP - 765

BT - Clinical and Basic Immunodermatology

PB - Springer International Publishing

ER -

Guggina LM, Gordon KB. Biologic therapies for psoriasis. In Clinical and Basic Immunodermatology: Second Edition. Springer International Publishing. 2017. p. 757-765 https://doi.org/10.1007/978-3-319-29785-9_43